Sundar.M
☆    

India,
2018-09-27 13:11
(2420 d 01:12 ago)

Posting: # 19330
Views: 4,529
 

 RSABE - Sequence [RSABE / ABEL]

Dear all,

What would be the advantages/disadvantages of following 6 sequences (TRR, RTR, RRT, RTT, TRT and TTR) in a RSABE design, instead of 3 sequences as per FDA recommendations. Your comments are highly appreciated.


Thanks
Sundar. M
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2018-09-28 15:15
(2418 d 23:08 ago)

@ Sundar.M
Posting: # 19337
Views: 3,774
 

 Suggested: TRT|RTR

Hi Sundar,

❝ […] advantages/disadvantages of following 6 sequences (TRR, RTR, RRT, RTT, TRT and TTR) in a RSABE design, instead of 3 sequences as per FDA recommendations.


Advantages
  • Additionally to the estimate of CVwR you get the one of CVwT (good to know esp. if your study is a pilot and you want to design a pivotal study where CVwR ≠ CVwT). In the partial replicate you have to assume that CVwR = CVwT.
  • If swR <0.294 (only ABE acceptable) no convergence issues in the mixed-effects model with the FDA’s covariance-specification.
Disadvantages
  • Sample size is a multiple of six (instead of three in the partial replicate and two in the three-period full replicate).
  • Design currently not implemented in PowerTOST’s function sampleN.RSABE().
If you want to kill two birds with one stone I recommend the three-period two-sequence full replicate design (TRT | RTR) instead.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Sundar.M
☆    

India,
2018-09-28 15:36
(2418 d 22:47 ago)

@ Helmut
Posting: # 19338
Views: 3,511
 

 Suggested: TRT|RTR

Thank you HS!
UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
90 visitors (0 registered, 90 guests [including 56 identified bots]).
Forum time: 14:23 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5